Guardant Health, Inc. (GH) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Guardant Health is a precision oncology company providing blood and tissue tests for cancer screening, monitoring, and treatment selection. Key products include the Guardant360 suite for advanced cancer and the Shield blood test for colorectal cancer screening, which received FDA approval in July 2024 and Medicare coverage in August 2024.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $265,196 | $191,476 | $700,755 | $537,202 |
| Net Loss | $(92,725) | $(107,754) | $(287,783) | $(325,367) |
| Loss Per Share (Basic/Diluted) | $(0.74) | $(0.88) | $(2.32) | $(2.66) |
| Operating Cash Flow | N/A | N/A | $(158,387) | $(175,345) |
| Cash & Equivalents (Total) | $689,515 | N/A | N/A | N/A |
| Convertible Debt (Principal) | $1,090,660 | $1,150,000 | N/A | N/A |
Note: Operating cash flow is presented for the nine-month period only as quarterly data is not explicitly isolated in the cash flow statement text provided.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 39% year-over-year to $265.2 million, driven by a 31% increase in Oncology revenue (volume growth to ~74,000 tests) and a significant surge in Screening revenue ($24.1 million vs. $1.0 million in Q3 2024) following the commercial launch of the Shield test.
- Expense Increases: Sales and marketing expenses rose 30% to $127.4 million due to commercial team expansion and Shield launch marketing. Cost of revenue increased 26% to $93.6 million, primarily due to higher sample volumes.
- Debt Restructuring: In February 2025, the company exchanged $659.3 million of its 2027 Convertible Notes for $600.0 million of new 2031 Convertible Notes, recognizing a $13.7 million gain on extinguishment.
- Stock Repurchase: The company repurchased $45.0 million of its common stock as treasury stock in February 2025.
Outlook, Risks, and Contingencies
- Legal Proceedings:
- TwinStrand/UW: A jury awarded $83.4 million in damages for patent infringement in late 2023. The company is appealing the verdict; an appeal regarding patent invalidity was heard in October 2025.
- Natera: The company won a false advertising trial in November 2024, with a final damages award of $287.0 million affirmed in July 2025.
- Tempus & CSHL: Active patent infringement lawsuits exist with Tempus AI and Cold Spring Harbor Laboratory. The company maintains these allegations are without merit.
- Regulatory & Reimbursement: The Shield test received Breakthrough Device designation for multi-cancer detection (MCD) in June 2025. Reimbursement remains a key variable, with the company estimating revenue based on variable consideration from payers.
- Liquidity: As of September 30, 2025, the company held $689.5 million in cash, cash equivalents, and restricted cash. Management believes this is sufficient to meet requirements for more than 12 months.
Investor Verification Checklist
- Shield Test Adoption: Verify the trajectory of Shield screening test volumes and reimbursement rates from Medicare and commercial payers post-launch.
- Legal Resolution: Monitor the status of the TwinStrand/UW appeal and the potential impact of the $83.4 million liability on future cash flows.
- Debt Conversion Risk: Assess the conversion terms of the remaining 2027 Notes and the new 2031 Notes relative to the current stock price to evaluate potential dilution.
- Operating Leverage: Track the ratio of Sales and Marketing expenses to revenue growth to determine if the heavy investment in the Shield launch is yielding sustainable margins.
- Inventory Levels: Review the increase in inventory ($90.5 million vs. $71.1 million prior year-end) to ensure it aligns with expected test volume growth and does not indicate obsolescence.